Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...
4d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 ...
The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback